Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic, addresses the challenges of treating chronic cough.
Symptoms of chronic cough vary among patients, and controlling them can be challenging, so the aim is to maximize for each patient how their symptoms affect them. Shared decision-making is very important to limit treatment risks and maximize the benefits to patients, noted Roxana Siles, MD, FAAAAI, staff in the Department of Allergy and Immunology at Cleveland Clinic and codirector of the Asthma Center at Cleveland Clinic.
Transcript
What do current clinical guidelines recommend for treatment of chronic cough?
As far as treatment guidelines, right now there’re no clear guidelines in terms of, “This is the medication of choice.” Once the common conditions are met and maximized in therapy, we’re left with things like cough suppressants. Those tend to have a lot of side effects that we have to worry about, including sedation. Some have more of an addictive potential. We do have neuromodulators that have been used for those patients who’ve been diagnosed with refractory cough. Again, those tend to have a lot of side effects also.
So again, different patients have different causes for their symptoms, and I think the key is to try to maximize how much of each condition is affecting this particular patient. But despite that, no matter what we do, it can be a challenge to keep symptoms controlled, which, unfortunately, affects patients’ quality of life and impacts their sleep in some cases, too.
Besides sedation and reduced quality of life, what are other adverse effects of chronic cough treatment?
I think those are the most common. When we think of cough suppressants, definitely those can certainly make patients very tired and even dizzy. But there’s always side effects with any medication we prescribe. For example, inhalers can sometimes lead to hoarseness or throat irritation that we have to be careful with. We always have to worry about long-term effects of using proton pump inhibitors or other antireflux therapies. So, this is where we have to really have shared decision-making and maximize the benefits by limiting the risks associated with potential adverse reactions to treatment.
Early Detection Strategies for Interstitial Lung Disease in Rheumatology: Janet Pope, MD, MPH
August 11th 2025Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic sclerosis, rheumatoid arthritis, and other connective tissue diseases.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Chronic Respiratory Diseases Linked to Other Noncommunicable Diseases in Vulnerable Countries
August 4th 2025Despite their devastating global impact, chronic respiratory diseases remain a hidden threat in low- and middle-income countries, often going undiagnosed in adults who are already battling other noncommunicable diseases.
Read More